UY39516A - Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión - Google Patents

Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión

Info

Publication number
UY39516A
UY39516A UY0001039516A UY39516A UY39516A UY 39516 A UY39516 A UY 39516A UY 0001039516 A UY0001039516 A UY 0001039516A UY 39516 A UY39516 A UY 39516A UY 39516 A UY39516 A UY 39516A
Authority
UY
Uruguay
Prior art keywords
composition
treatment
hypertension
prevention
vascular disease
Prior art date
Application number
UY0001039516A
Other languages
English (en)
Inventor
John J M Wiener
Cheryl A Grice
Daniel J Buzard
Justin S Cisar
Olivia D Weber
Amy Allan
Nicholas Raffaele
Jeanne V Moody
Michael B Shaghafi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of UY39516A publication Critical patent/UY39516A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)

Abstract

En la presente se proporcionan compuestos de 6-azaespiro[2.5]octano-6-carboxilato de 1,1,1,3,3,3-hexafluoropropan-2-ilo sustituidos y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos y composiciones proporcionados en la presente son útiles como inhibidores de MAGL. Además, los compuestos y composiciones y proporcionados en la presente son útiles para el tratamiento de enfermedades y trastornos que se benefician de la inhibición de MAGL.
UY0001039516A 2020-11-13 2021-11-11 Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión UY39516A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063113662P 2020-11-13 2020-11-13

Publications (1)

Publication Number Publication Date
UY39516A true UY39516A (es) 2022-05-31

Family

ID=78709459

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039516A UY39516A (es) 2020-11-13 2021-11-11 Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión

Country Status (17)

Country Link
US (2) US11434222B2 (es)
EP (1) EP4244208A1 (es)
JP (1) JP2023549051A (es)
KR (1) KR20230107225A (es)
CN (1) CN116547274A (es)
AR (1) AR124057A1 (es)
AU (1) AU2021379081A1 (es)
CA (1) CA3196119A1 (es)
CL (1) CL2023001339A1 (es)
CO (1) CO2023004649A2 (es)
CR (1) CR20230203A (es)
DO (1) DOP2023000086A (es)
IL (1) IL301818A (es)
MX (1) MX2023005576A (es)
TW (1) TW202229255A (es)
UY (1) UY39516A (es)
WO (1) WO2022101412A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
WO2023213854A1 (en) * 2022-05-04 2023-11-09 H. Lundbeck A/S Crystalline form of 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazin-3-ylcarbamoyl)-6 azaspiro[2.5]octane-6-carboxylate as monoacylglycerol lipase inhibitor.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2008023720A1 (ja) 2006-08-23 2010-01-14 アステラス製薬株式会社 ウレア化合物又はその塩
US20120083476A1 (en) 2009-06-05 2012-04-05 Janssen Pharmaceutica Nv Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase
PL2800565T3 (pl) 2012-01-06 2020-09-21 Lundbeck La Jolla Research Center, Inc. Związki karbaminianowe i sposoby ich wytwarzania oraz zastosowanie
LT2900669T (lt) 2012-09-25 2019-11-11 Hoffmann La Roche Heksahidropirol[3,4-c]pirolo dariniai ir susiję junginai kaip autotaksino (atx) inhibitoriai ir kaip lizofosfatidinės rūgšties (lpa) gamybos inhibitoriai, skirti gydyti pvz., inkstų ligas
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
CA2943874A1 (en) 2014-04-04 2015-10-08 X-Rx, Inc. Substituted spirocyclic inhibitors of autotaxin
JP2018513119A (ja) 2015-03-18 2018-05-24 アビデ セラピューティクス，インク． ピペラジンカルバメート、およびピペラジンカルバメートを製造ならびに使用する方法
JP6832914B2 (ja) 2015-07-31 2021-02-24 ファイザー・インク Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
US10030020B2 (en) 2016-05-12 2018-07-24 Abide Therapeutics, Inc. Spirocycle compounds and methods of making and using same
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
AU2018326497A1 (en) 2017-08-29 2020-02-20 H. Lundbeck A/S. Spirocycle compounds and methods of making and using same
BR112020004101A2 (pt) 2017-08-29 2020-09-24 Lundbeck La Jolla Research Center, Inc. compostos de espirociclo e métodos para produzir e usar os mesmos

Also Published As

Publication number Publication date
MX2023005576A (es) 2023-05-29
US20220153721A1 (en) 2022-05-19
WO2022101412A1 (en) 2022-05-19
DOP2023000086A (es) 2023-06-30
AR124057A1 (es) 2023-02-08
TW202229255A (zh) 2022-08-01
IL301818A (en) 2023-06-01
CO2023004649A2 (es) 2023-05-08
US20240018120A1 (en) 2024-01-18
CR20230203A (es) 2023-06-14
JP2023549051A (ja) 2023-11-22
AU2021379081A1 (en) 2023-05-18
CA3196119A1 (en) 2022-05-19
CN116547274A (zh) 2023-08-04
US11434222B2 (en) 2022-09-06
CL2023001339A1 (es) 2023-10-20
KR20230107225A (ko) 2023-07-14
EP4244208A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
CL2023001738A1 (es) Inhibidores de prmt5
CL2019000221A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1.
UY39516A (es) Composición para el tratamiento de una enfermedad vascular, composición para la prevención de una enfermedad vascular, composición para el tratamiento de la hipertensión, y composición para la prevención de la hipertensión
UY39149A (es) Compuestos y métodos para el tratamiento de covid-19
AR105808A1 (es) Compuestos de amida para el tratamiento de trastornos médicos
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
CL2022003360A1 (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578)
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CL2022000875A1 (es) Inhibidores del factor d del complemento para administración oral
UY39150A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CO2022005926A2 (es) Inhibidores del factor d del complemento para administración oral
AR127470A1 (es) Inhibidores de lrrk2
CO2022011258A2 (es) Pirazolo-pirimidinas sustituidas y usos de las mismas
CO2023004420A2 (es) Compuestos heterocíclicos como inhibidores del bromodominio cbp/ep300
CL2022002531A1 (es) Moduladores de nlrp3
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2022011697A (es) Inhibidores de ciclofilina y usos de los mismos.
AR127243A1 (es) Compuestos, composiciones farmacéuticas y métodos para el tratamiento, prevención o manejo de trastornos hiperproliferativos
ECSP23034732A (es) Un inhibidor de magl
CL2021001944A1 (es) Derivados de aminoácidos para el tratamiento de enfermedades inflamatorias
AR125372A1 (es) Compuestos, composiciones y métodos para el tratamiento de trastornos
CL2021001093A1 (es) Compuestos, composiciones, y métodos para modular la actividad cdk9